ATE198158T1 - Verfahren zur behandlung geschädigter und verminderter zellen - Google Patents

Verfahren zur behandlung geschädigter und verminderter zellen

Info

Publication number
ATE198158T1
ATE198158T1 AT93920456T AT93920456T ATE198158T1 AT E198158 T1 ATE198158 T1 AT E198158T1 AT 93920456 T AT93920456 T AT 93920456T AT 93920456 T AT93920456 T AT 93920456T AT E198158 T1 ATE198158 T1 AT E198158T1
Authority
AT
Austria
Prior art keywords
treating damaged
degraded cells
treating
degraded
cells
Prior art date
Application number
AT93920456T
Other languages
English (en)
Inventor
David A Williams
Steven C Clark
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst filed Critical Genetics Inst
Application granted granted Critical
Publication of ATE198158T1 publication Critical patent/ATE198158T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Dicing (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93920456T 1992-09-02 1993-09-01 Verfahren zur behandlung geschädigter und verminderter zellen ATE198158T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/941,372 US5460810A (en) 1992-09-02 1992-09-02 Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11
PCT/US1993/008247 WO1994005318A1 (en) 1992-09-02 1993-09-01 Method of treating cell damage or depletion

Publications (1)

Publication Number Publication Date
ATE198158T1 true ATE198158T1 (de) 2001-01-15

Family

ID=25476360

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93920456T ATE198158T1 (de) 1992-09-02 1993-09-01 Verfahren zur behandlung geschädigter und verminderter zellen

Country Status (11)

Country Link
US (2) US5460810A (de)
EP (1) EP0671934B1 (de)
JP (1) JP2828778B2 (de)
AT (1) ATE198158T1 (de)
CA (1) CA2142879C (de)
DE (1) DE69329779T2 (de)
DK (1) DK0671934T3 (de)
ES (1) ES2155834T3 (de)
GR (1) GR3035413T3 (de)
PT (1) PT671934E (de)
WO (1) WO1994005318A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US5601814A (en) * 1994-08-05 1997-02-11 Schering Corporation Use of IL-6 to treat toxic shock
AU5717196A (en) * 1995-05-05 1996-11-21 Schering Corporation Restoration of progenitor cells after antiproliferative ther apy treatments
US5760189A (en) * 1995-06-02 1998-06-02 Genetics Institute, Inc. Protein recovery & purification methods
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5679339A (en) * 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US6540993B1 (en) * 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US5863529A (en) * 1995-09-20 1999-01-26 Mayo Foundation For Medical Education And Research Suppression of demyelination by interleukin-6
US5814308A (en) * 1996-03-26 1998-09-29 Zhang; Ke Methods for the treatment of gastrointestinal tract disorders
WO1998018483A1 (en) * 1996-10-25 1998-05-07 Bristol-Myers Squibb Company Oncostatin m for treating inflammation
AUPO439396A0 (en) * 1996-12-24 1997-01-23 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment and prophylaxis
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
US6953777B2 (en) * 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
EP1096948A4 (de) * 1999-04-15 2004-04-07 Inst Genetics Llc Verwendung von interleukin-11 zur behandlung gastrointestinaler krankheiten
CA2376358A1 (en) * 1999-06-08 2000-12-14 Genetics Institute, Inc. Use of interleukin-11 to treat hemorrhagic shock
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
WO2001041779A2 (en) * 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
US20080069796A1 (en) * 2006-07-31 2008-03-20 Kim Jong-Mook Low Dose Treatment with an Interleukin-11 Analog
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
JP5664623B2 (ja) * 2012-09-26 2015-02-04 東レ株式会社 改質されたインターロイキン−１１とその製造方法
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
US20220096602A1 (en) * 2019-02-27 2022-03-31 Rutgers, The State University Of New Jersey Lif therapy for inducing intestinal epithelial cell regeneration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082658A (en) * 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
IL97779A (en) 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5214066A (en) * 1990-04-18 1993-05-25 Brigham And Women's Hospital Method for producing an animal model for inflammatory bowel disease including ulcerative colitis
AU666866B2 (en) * 1991-08-30 1996-02-29 Fred Hutchinson Cancer Research Center Hybrid cytokines

Also Published As

Publication number Publication date
US5437863A (en) 1995-08-01
WO1994005318A1 (en) 1994-03-17
AU677236B2 (en) 1997-04-17
JP2828778B2 (ja) 1998-11-25
PT671934E (pt) 2001-05-31
ES2155834T3 (es) 2001-06-01
AU5099993A (en) 1994-03-29
EP0671934B1 (de) 2000-12-20
DE69329779D1 (de) 2001-01-25
US5460810A (en) 1995-10-24
CA2142879C (en) 2000-10-31
JPH08500838A (ja) 1996-01-30
DK0671934T3 (da) 2001-02-26
GR3035413T3 (en) 2001-05-31
EP0671934A1 (de) 1995-09-20
EP0671934A4 (de) 1996-10-16
DE69329779T2 (de) 2001-08-09

Similar Documents

Publication Publication Date Title
DE69329779D1 (de) Verfahren zur behandlung geschädigter und verminderter zellen
DE3854276D1 (de) Kathodenzerstäubungsverfahren und Vorrichtung zur Durchführung desselben.
DE3579891D1 (de) N-((4,6-dimethoxypyrimidin-2-yl)aminocarbonyl)-3-trifluoromethylpyridin-2-sulfonamide oder salze davon, diese enthaltendes herbizides mittel und verfahren zur herstellung dieser verbindung.
DE3860266D1 (de) Optisch aktive (meth)acrylamide, verfahren zu ihrer herstellung und ihre verwendung zur racematspaltung.
DE69609222D1 (de) Partikel auf Polyaminosäure(n)basis zur Verwendung als Wirkstoffträger sowie deren Herstellungsverfahren
DE3867743D1 (de) Benzamid-derivat, verfahren zu dessen herstellung und pflanzenwachstumsregulator.
DE3585542D1 (de) Methoden zur herstellung biologisch aktiver membranen und ihre verwendungen.
EP0963197A4 (de) Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten
DE3484416D1 (de) Intraalveolare vorrichtung zur verabreichung von wirkstoffen zum behandeln periodontaler krankheiten.
ES2056071T3 (es) Triazolinonas substituidas.
DE3861642D1 (de) Katalysator zur wasserstoffbehandlung von kohlenwasserstoffen und methode zu dessen herstellung.
ES8403157A1 (es) Un metodo de preparar sustancias biologicamente activas que tienen actividad anti-tumoral.
DE3852402D1 (de) Galliumnitridartige Halbleiterverbindung und daraus bestehende lichtemittierende Vorrichtung sowie Verfahren zu deren Herstellung.
ATE72625T1 (de) Verfahren und vorrichtung zur herstellung zusammenhaengender elastischer bandagen.
AT387266B (de) Reib- bzw. gleitkoerper, sowie verfahren und vorrichtung zu dessen herstellung
DE3889479D1 (de) Mit Nieder-pI-Protein beschichtete Membranstruktur und Verfahren zu ihrer Herstellung und Verwendung.
DE68917642D1 (de) Verfahren zur kontinuierlichen Züchtung von haftenden tierischen Zellen.
DE3669063D1 (de) Verfahren zur desinfektion von lokalen gegen kokkizide oozysten.
ATE194033T1 (de) Verfahren zur identifizierung von stoffen mit potentieller herbizider oder wachstumsregulatorischer wirkung mittels pflanzlicher transporterproteine
AT382619B (de) Verfahren zur herstellung von neuen optisch aktiven und racemischen trans- und/oder cis-1-(2'-(alkoxycarbonyl)-2'-(hydroxyimino) -aethyl)-1-alkyl-1,2,3,4,6,7,12,12b-octahydroindolo(2,3-a)chinolizinen
DE3680247D1 (de) Verwendung eines antithrombogenen synthetischen elastomers sowie verfahren zu dessen herstellung.
DE3867918D1 (de) Wachstumspromotor fuer bifidobacterium-arten, prozess zu dessen herstellung und verfahren fuer dessen anwendung.
DE3872160D1 (de) Morpholinylsilane und verwendung zur beherrschung von pflanzenkrankheiten, verursacht durch pilze.
ATE343930T1 (de) Verfahren zur bekämpfung von fischmycosen und einzelligen ektoparasiten
DE3686148D1 (de) Lymphotoxin-gen, verfahren zu dessen herstellung und lymphotoxin.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
REN Ceased due to non-payment of the annual fee